# A Safety and Efficacy Study of DRL-17822, a Cholesteryl Ester Transfer Protein (CETP) Inhibitor, in Patients With Abnormal Cholesterol Levels

> **NCT01388816** · PHASE2 · COMPLETED · sponsor: **Dr. Reddy's Laboratories Limited** · enrollment: 176 (actual)

## Conditions studied

- Type II Hyperlipidemia

## Interventions

- **DRUG:** DRL-17822 or placebo

## Key facts

- **NCT ID:** NCT01388816
- **Lead sponsor:** Dr. Reddy's Laboratories Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-07
- **Primary completion:** 2012-05
- **Final completion:** 2012-06
- **Target enrollment:** 176 (ACTUAL)
- **Last updated:** 2014-04-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01388816

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01388816, "A Safety and Efficacy Study of DRL-17822, a Cholesteryl Ester Transfer Protein (CETP) Inhibitor, in Patients With Abnormal Cholesterol Levels". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT01388816. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*